1. HBW Insight
  2. >>Health
  3. >>Policy & Regulation
  4. >>Legislation

House Maintains Momentum For OTC Monograph Reform, Senate Regard TBD

 
• By Malcolm Spicer

House passes, with large bipartisan support, Pandemic and All-Hazards Preparedness and Advancing Innovation Act, which includes Over-the-Counter Monograph Safety, Innovation, and Reform Act for modernizing FDA's system overseeing vast majority of OTC drugs. Provisions would allow FDA to use administrative orders, rather than notice-and-comment rulemakings, to add ingredients, dosages, delivery formats or indications to monographs, or drugs marketed without approved applications.

The House Energy and Commerce Committee didn't wait long in the 116th Congress to send to the floor legislation that would overhaul FDA's OTC monograph process. The Senate, on the other hand, has been willing to wait on considering the changes.

The House on Jan. 8 passed, in a 401-17 vote showing large bipartisan support, the Pandemic and All-Hazards Preparedness and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

Combat Meth Act PSE Daily Purchase Limit Once Too High For States Now Embraced By Most

 
• By Malcolm Spicer

Limits so effective that states are relaxing restrictions they previously set exceeding the nationwide limit Congress imposed in Combat Meth Act in 2006 on the amount of PSE, as well as a second meth precursor, ephedrine, in OTC drugs consumers can purchase daily.

Senate HELP Committee Adds Sunscreen Regulation Overhaul To OMUFA Reauthorization

 
• By Lauren Nardella

OMUFA reauthorization bill including amendment with sunscreen regulation provisions passed by Senate committee, which also approved other provisions not included in House OMUFA bill.

Sunscreen Regulation Reforms Still Could Hitch Ride On Senate OMUFA Reauthorization Bill

As stakeholders and lawmakers pin their hopes on OMUFA reauthorization as a vehicle for enacting sunscreen regulatory changes, Senate version of the bill could be the ticket after a sunscreen-specific amendment withdrawn in the House.

Democrats Slam Trump’s ‘Sledgehammer’ On FDA

 
• By Malcolm Spicer

“We cannot ignore how Trump has taken a sledgehammer to the FDA ability to evaluate new drugs,” says California’s Nanette Diaz Barragán of California during Energy and Comme e markup discussion of five-year reauthorization of FDA’s OMUFA.

More from Policy & Regulation

Combat Meth Act PSE Daily Purchase Limit Once Too High For States Now Embraced By Most

 
• By Malcolm Spicer

Limits so effective that states are relaxing restrictions they previously set exceeding the nationwide limit Congress imposed in Combat Meth Act in 2006 on the amount of PSE, as well as a second meth precursor, ephedrine, in OTC drugs consumers can purchase daily.

New US FDA CDER Director Pledges No Politics In Approvals, Adds Higher Ups Can Overturn

 
• By Sarah Karlin-Smith

New CDER Director George Tidmarsh promised to keep politics out of drug approvals, but suggested during a meeting with staff that he could not insulate the drug center from political pressures coming from those above him.

FDA Whips Up Sunscreen Delivery Format Warnings To Firms In US, Israel, Sweden

FDA admonishes five marketers for straying from approved sunscreen dosage forms in recent warning letters. Violative delivery formats render products unapproved drugs and misbranded.